Author:
Juárez-Soto A.,Garín-Ferreira J.M.,Rodríguez-Fernández A.,Tirado-Hospital J.L.,González-Serrano M.T.,Moreno-Jiménez J.,Medina-López R.,Baena-González V.
Reference37 articles.
1. New multidisciplinary prostate bone metastases clinic: first of its kind in Canada;Goh;Curr Oncol.,2007
2. Guidance for Industry. Clinical trail endpoints for the approval of cancer drugs and biologics. Food and Drug Administration [consultado 17 Ene 2018]. Disponible en: http://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf
3. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer;Ross;J Urol.,2002
4. Clinical features of metastatic bone disease and risk of skeletal morbidity;Coleman;Clin Cancer Res.,2006
5. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours;Durán;Clin Transl Oncol.,2014